Lumida
/OPK
⌘K
OPKO Health Inc

OPKO Health Inc

OPK
$1.57USD+5.37%+0.08 today

MARKET CAP

1.2B

P/E (TTM)

FWD P/E

DAY RANGE

$1 – $2

52W RANGE

$1
$2

AI Summary

Stalk
Buy NowMedium

OPK is in a Stage 2 advancing uptrend with a primary Bearish Exhaustion pattern signaling seller fatigue and a likely bottoming bounce. Price is currently pulling back into rising 9- and 20-day EMAs on neutral RSI and moderate volume, offering a high-selectivity speculative entry. With no mean-reversion override, the medium-term bias remains bullish, and buying now into this pullback aligns with the speculative strategy’s emphasis on clear structural support.

  • Ended Q2 with $300M+ cash cushioning operations and R&D
  • Raised full-year revenue outlook to $560–585M, up from prior
  • Diagnostics revenue fell to $74.5M in Q2 from $101.1M prior year
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.8B$1.0B$863.5M$713.1M$606.9M
YoY %+23.6%-43.4%-14.0%-17.4%-14.9%
P / Sales1.8x0.9x1.4x1.4x1.6x
EV / Sales2.1x1.3x2.0x2.0x2.0x
Gross Profit, Adj.$581.5M$288.2M$318.1M$218.5M$205.9M
YoY %+7.5%-50.4%+10.4%-31.3%-5.8%
Margin %32.8%28.7%36.8%30.6%33.9%
EV / Gross Profit6.4x4.6x5.4x6.5x6.0x
EBITDA, Adj.$64.3M$-137.5M$-51.7M$-175.4M$-127.4M
YoY %-53.8%-313.9%+62.4%-239.1%+27.4%
Margin %3.6%-13.7%-6.0%-24.6%-21.0%
EV / EBITDA57.5x-9.7x-33.0x-8.1x-9.7x
EBIT$-12.8M$-244.8M$-157.0M$-273.6M$-219.0M
YoY %-122.1%-1818.9%+35.9%-74.2%+19.9%
Margin %-0.7%-24.4%-18.2%-38.4%-36.1%
EV / EBIT-289.8x-5.4x-10.9x-5.2x-5.7x
Net Income$-30.1M$-328.4M$-188.9M$-53.2M$-225.7M
YoY %-198.6%-989.5%+42.5%+71.8%-324.0%
Net Margin-1.7%-32.7%-21.9%-7.5%-37.2%
EPS (GAAP)-$0.05-$0.46-$0.25-$0.08-$0.30
YoY %-200.0%-820.0%+45.7%+68.0%-275.0%